Luciferase News and Research

RSS

Importance of Numb-associated kinases in SARS-CoV-2 infection

A new study posted to the bioRxiv* preprint server has focussed on assessing four members of the NAK family that are associated with SARS-CoV-2 infection. These kininases could act as a target for the development of effective COVID-19 therapeutics.

23 Mar 2022

Angiotensin-converting enzyme 2 allosteric binders found to be effective against SARS-CoV-2

Researchers reported a hybrid approach comprising computational models and high throughput screening to discover allosteric ACE2 binders inhibiting viral replication without interrupting ACE2 renal, pulmonary, immune, and cardiovascular functions.

22 Mar 2022

A circRNA COVID vaccine with potential to neutralize SARS-CoV-2 variants

Researchers demonstrate the broad neutralization potential of a strategically engineered circRNA using mice as a model system.

21 Mar 2022

Neutralizing antibody responses against parental SARS-CoV-2 strain as well as against Omicron BA.1 and BA.2 variants

Researchers evaluated the immune responses in individuals vaccinated with the BNT162b2 vaccine.

21 Mar 2022

Aminoglycoside antibiotic geneticin shows selective antiviral effect against SARS-CoV-2

Researchers elucidated antiviral activities of aminoglycoside geneticin against seven SARS-CoV-2 variants using different cell lines and respiratory tissues.

11 Mar 2022

A new view of SARS-CoV-2 genome structure

Researchers performed DMS mutational profiling with sequencing and DREEM clustering to determine the SARS-CoV-2 RNA secondary structure.

8 Mar 2022

Combating COVID cytokine storm with targeted nucleic acid therapies

Researchers examine current nucleic acid-based treatments against COVID-19 and their methods of action.

6 Mar 2022

Encouraging in vitro results with SARS-CoV-2-spike-specific polyclonal antibody fragments

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated the potent neutralizing ability of a polyclonal equine antibody (Ab), FBR-002, against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), including Omicron.

28 Feb 2022

Study suggests non-classical inhibition of TBK1/IKKε is protective against severe COVID-19 immunopathology in vivo

A study posted suggested the inhibition of TBK1 and its homolog KKε could decrease the severity of COVID-19.

21 Feb 2022

Study examines lyophilized mRNA-lipid nanoparticle vaccines with long-term stability

A new study explored the high immunogenicity and stability of lyophilized mRNA-LNP vaccines in relation to SARS-CoV-2.

16 Feb 2022

The in vitro selection of a remdesivir-resistant SARS-CoV-2 mutation

Researchers select and study an RDV-resistant virus by serial passaging of wild type SARS-CoV-2 in the presence of increasing concentrations of RDV.

15 Feb 2022

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

A new study published demonstrated the in vitro potencies of RDV and GS-441524 through PRA, and nucleoprotein ELISA against SARS-CoV-2 and other VOC/VOIs isolates with specific substitutions in Nsp12.

15 Feb 2022

Study shows expression of viral proteases may be used to quantitate SARS-CoV-2 infected cells

A new study describes a new method to quantify SARS-CoV-2 infection, which is much simpler and faster compared to existing methods.

14 Feb 2022

Study provides evidence for spike protein-independent attenuation of SARS-CoV-2 Omicron variant

A new study provided the structural basis for a robust interaction between the receptor-binding domain of the SARS-CoV-2 Omicron spike protein and mouse ACE2.

13 Feb 2022

Rapid generation and evaluation of an mRNA vaccine candidate specific to Omicron

A recent study demonstrated the development of a potential SARS-CoV-2 Omicron variant-specific mRNA vaccine candidate.

10 Feb 2022

Study compares the neutralizing potential of antibodies against two Omicron variants

A new study investigates if the two SARS-CoV-2 Omicron variants BA.1 and BA.2 are comparable with respect to their ability to evade the host immunity induced by vaccination or prior infection.

9 Feb 2022

SARS-CoV-2 virus co-opts intrinsic cellular machinery to suppress interferon production

In a recent study posted to the bioRxiv* preprint server, researchers evaluated the mechanism of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-associated inflammatory marker interferon (IFN) repression in hosts.

25 Jan 2022

Study shows SARS-CoV-2 prompts NLRP3 inflammasome activation through spike-ACE2 receptor interaction

New research assesses the NLR family pyrin domain containing 3 (NLRP3) inflammasome activation in response to SARS-CoV-2 and its spike protein, and the effects of this exposure in the presence of a-synuclein protein aggregate fibrils.

17 Jan 2022

Study demonstrates that intra-host SARS-CoV-2 variants with reduced infectivity are developed during infection

A new paper discusses the appearance of quasi-species in a single host with prolonged infection, with different rates of infectivity and sensitivity to neutralization by antibodies elicited by the Pfizer vaccine or those present in convalescent plasma.